Pradaxa ® (dabigatran etexilate) Video Statement
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New publication in The Lancet describes effective reversal of Pradaxa ® in healthy volunteers
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Positive CHMP opinion for Pradaxa ® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim ' s innovation promise in cardiovascular diseases (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New findings from two studies support substantial benefit of Pradaxa ® for prevention of recurrent deep vein thrombosis and pulmonary embolism
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa ® compared to warfarin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New long-term treatment data confirms consistent benefit and safety profile of Pradaxa ® beyond 6 years
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa ® (dabigatran etexilate) in expanded patient populations
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Pradaxa ® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New long-term data reinforce safety profile of Pradaxa ® for stroke prevention in AF
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
FDA approves Pradaxa ® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New Pradaxa ® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
FDA and EMA reaffirm important health benefits and safety of Pradaxa ® (dabigatran etexilate) for patients with atrial fibrillation
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Boehringer Ingelheim Presents New idarucizumab (Praxbind ®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
